CHIDINMA P AMAKIRI

Allopathic & Osteopathic Physicians|Internal Medicine DALLAS, TX NPI 1962039255

General Payments — all program years on this page

$561.09

  • Category: General Payments
  • Program years: PY2023–2024
  • Record count: 23
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $540.28 across 22 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $540.2822

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2023 $20.811
2024 $540.2822

Records — PY2024 (22)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1082150435 Dynavax Technologies Corporation $21.54 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096836908 Novo Nordisk Inc $18.56 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101332222 E.R. Squibb & Sons, L.L.C. $26.67 07/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111516095 Amgen Inc. $13.10 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114540603 Exact Sciences Corporation $14.34 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116530546 GlaxoSmithKline, LLC. $17.49 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117189386 Amgen Inc. $14.21 06/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117189388 Amgen Inc. $14.38 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131264454 PFIZER INC. $20.61 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136096107 Lilly USA, LLC $17.23 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136097744 Lilly USA, LLC $96.19 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136097746 Lilly USA, LLC $18.54 06/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136097748 Lilly USA, LLC $11.25 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136113586 Lilly USA, LLC $11.33 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136117605 Lilly USA, LLC $18.05 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139321792 Astellas Pharma US Inc $19.78 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139359125 Astellas Pharma US Inc $17.78 06/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139380146 Astellas Pharma US Inc $110.27 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139380604 Astellas Pharma US Inc $11.12 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139436310 Astellas Pharma US Inc $11.96 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139567115 SANOFI-AVENTIS U.S. LLC $15.20 11/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141911704 Merck Sharp & Dohme LLC $20.68 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.